Scientists create a new ozempic replacement targeting 30% weight loss

Researchers think they may have the next and best version of Ozempic in progress.

At TUFTS University, scientists have developed a new medication that aims to increase weight loss while reducing nausea, muscle loss and weight withdrawal from popular GLP-1 drugs.

The objective is that the drug “quadruple action” to reach a lasting weight loss of up to 30% – corresponding to the effectiveness of bariatric surgery, which reduces the size of the stomach, according to a press release from the study.

Could GLP-1 weight loss drugs like Ozempic become the “all medication”?

How is the medication different

Semaglutid drugs, such as ozempique and Wegovy, imitate the natural GLP-1 hormone (Peptide-1 of the glucagon type), while shooting (such as mounjaro and zepbound) target GLP-1 receptors and GIP (dependent glucose-glucose) receptors.

Scientists have developed a new drug that aims to increase weight loss while reducing nausea, muscle loss and weight withdrawal from popular GLP-1 drugs. (istock)

The new tufts drug targets a combination of four hormones – GLP -1, GIP, Glucagon (the insulin counterpart) and the YY peptide, which reduces hunger, slows the emptying of the stomach and can promote the combustion of fat.

“We have built a single experimental peptide that works like four hormones at the same time, so we don’t support a too strong button,” the author Tristan Dinsmore, PHD, researcher at Tufts University, told Fox News Digital.

5 carbohydrates full of protein that can help you lose weight and develop muscles, says dietitian

“Instead, we push four ‘gradator” together to manage appetite, blood sugar and energy consumption. “”

Because GLP – 1 and Pyy can contribute to nausea at higher doses, researchers relied on GIP, which is known to alleviate nausea, to “balance things,” said Dinsmore.

“We have built a single experimental peptide that works like four hormones at a time, so we don’t press a button too hard.”

“Beyond helping fullness and glucose control, GIP signaling has anti-nausea effects-it can even block nausea in preclinical models, which is why we prioritize it in the mixture,” he continued.

“By adding Pyy to the GLP trio – 1 / GIP / GLUCAGON, we hope to count less on GLP – 1 and glucagon to cause weight loss, potentially reducing the risk of nausea (GLP -1 / PYY) and a risk of blood sugar (glucagon) while retaining the advantages.”

Because GLP – 1 and Pyy can contribute to nausea at higher doses, researchers have relied on GIP, which is known to alleviate nausea, to “balance things”, said one of the researchers. (istock)

The drug is still at the experimental / preclinical stage and has not yet been tested in human trials.

The development of the drug was published in the Journal of the American Chemical Society.

Doctors react

Dr. Brett Osborn, an expert in neurosurgeon and Florida longevity, is an ardent defender of GLP-1 drugs.

“There are a lot of very effective GLP-1 agonists just in front of us.”

“The GLP-1s with a single agent like Ozempic work for most people,” Osborn, who was not involved in the TUFTS study in Fox News Digital, said. “The side effects are manageable when an experienced doctor supervises you.”

“We don’t need more drugs to deal with the same chronic problem that has overwhelmed the world more and more,” he added. “There are a lot of very effective GLP-1 agonists just in front of us.”

Obesity is estimated that more than 40% of American adults have been linked to dozens of diseases, including type 2 diabetes, heart disease, brain vascular accidents, sleep apnea, high blood pressure and several types of cancer. (istock)

The greatest risks with GLP-1 are muscle loss and malnutrition of the sub-line, he said. To avoid this, the doctor highlights the need for adequate daily protein and coherent force training.

To treat the “chronic” obesity disease, OSBORN recommends microdosage or intermittent GLP-1 dosage, associated with nutrition, progressive resistance, hydration and sleep.

A Mediterranean diet associated with other lifestyle changes the risk of diabetes

“Essentially, use the drug that works and combine it with disciplined habits,” he advised. “I have used this approach for years, like many of my patients, with excellent long -term tolerance.”

Sue Decotiis, MD, medical doctor with weight loss in New York, noted that appetite control, improving metabolism and increased fat combustion – while balancing the interactions of blood sugar and insulin – is a “complex function”.

“Even with new mechanisms added to weight loss drugs, individual patients will have various answers in the amount of fat they lose,” said an expert. (istock)

“The additional mechanisms offered by new drugs can help some, but not necessarily most weight loss patients,” said Decotiis, who was not involved in the study, at Fox News Digital.

“Even with new mechanisms added to weight loss drugs, individual patients will have various responses of the amount of fat they lose.”

Click here to obtain the Fox News app

She noted that her patients who take GLP-1 generally do not undergo muscle and bone loss.

“Good care in medical weight loss should include patients with a body composition scale and surveillance protein, fiber and excellent hydration,” she said.

Future limitations and research

There were some limits of the new drug, recognized the researchers.

“The additional mechanisms offered by new drugs can help some, but not necessarily most patient loss patients.”

“These are design research that presents the potential of the next generation and perhaps even suitable drugs,” Dinsmore told Fox News Digital. “Our data comes from cells based on cells, not animals or humans (still).”

“The choice of the safest and most effective balance of the four ways will require in-vivo (living) studies and clinical trials.”

Click here to register for our Health Newsletter

People using drug-based drugs should stick to the advice of their clinician, advised Dinsmore.

“This is not a medication you can get today,” he said about the new medication. “Our work is a concept of next generation which aims to improve results and reduce nausea by distributing work on four hormones rather than overloading one.”

Obesity is estimated that more than 40% of American adults have been linked to dozens of diseases, including type 2 diabetes, heart disease, brain vascular accidents, sleep apnea, high blood pressure and several types of cancer.

For more health items, visit www.foxnews.com/health

“What motivates us is the idea that we can design a single drug to treat obesity and simultaneously alleviate the risk of developing a long list of health problems that afflict society,” said the author of the Krishna Kumar co-study, professor of Robinson chemistry at Tufts.